Gene · 2621
NIH grants2,018
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1,381 to 1,400 of 2,018
Download this page as JSON| Grant | Title | GAS6 papers | Newest fiscal year |
|---|---|---|---|
| R01HL114907 | Contribution of Toll-like Receptors in the Pulmonary Response to Nanoparticles an | 1 | 2016 |
| R01HL115557 | Harmful effects of red blood cell transfusions are mediated by iron | 1 | 2016 |
| R01LM009239 | Image Mining for Comparative Analysis of Expression Patterns in Tissue Microarray | 1 | 2016 |
| R01MH094343 | Genetic Influences on Human Neuroanatomical Shapes | 1 | 2016 |
| R01MH097659 | Systems Biology of Cognitive Decline in Older Adults with HIV Infection | 1 | 2016 |
| R01NS075212 | Vascular biology of the human blood-nerve barrier | 1 | 2016 |
| R03CA191430 | Organ specific macrophages and the regulation of disseminated tumor cell fate | 1 | 2016 |
| R13ES027302 | 2016 SETAC Asia/Pacific Conference | 1 | 2016 |
| R15AI117474 | Macrophage polarization by C1q and related molecules | 1 | 2016 |
| R15NS096694 | Novel Regulation of Receptor Tyrosine Kinases by ASM (Acidic Sphingomyelinase) | 1 | 2016 |
| R21AI114549 | ENDOTHELIAL FACTORS IN CRYPTOCOCCAL MIGRATION ACROSS THE BLOOD-BRAIN BARRIER | 1 | 2016 |
| R21AI117282 | Separation of GVHD and GVT effects by a TCR signaling mutation | 1 | 2016 |
| R21CA187843 | Role of Axl in docetaxel resistance in prostate cancer | 1 | 2016 |
| R21CA191622 | Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer | 1 | 2016 |
| R21ES023627 | Differential miRNA expression & progression of arsenic induced skin cancers | 1 | 2016 |
| R21NS091710 | Longitudinal Monitor of Microglia Activation After Stroke with SPION-enhanced MRI | 1 | 2016 |
| R25HG007515 | Advanced Techniques for Single Cell Transcriptomics | 1 | 2016 |
| R33AI100186 | Metabolomics-based discovery of small molecule biomarkers for noninvasive dengue | 1 | 2016 |
| R37NS036251 | Molecular Mechanisms in Synaptic Vesicle Recycling | 1 | 2016 |
| R41NS097047 | Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies | 1 | 2016 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2621/grants?page=70